Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Monosialotetrahexosylganglioside, also known as GM1, is a ganglioside—a type of glycosphingolipid with one sialic acid residue—found in animal tissues and particularly abundant in the nervous system. It acts as a neurotrophic factor and is used for its neuroprotective properties. Upon administration, GM1 can prevent neurologic damage and promote regeneration of damaged neurons by enhancing neurotrophic repair mechanisms, increasing the production of neurotrophins, and augmenting neurite outgrowth[1][2]. It has been investigated for use in conditions such as hypoxic ischemic encephalopathy, oxaliplatin-induced neuropathy in cancer patients, acute spinal cord injury, and other central or peripheral neurological injuries[3][5][8]. The compound is typically extracted from porcine brain tissue[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on monosialotetrahexosylganglioside.